CYP | Parametera | Sample Size | Ratio | 90% CI | CVintra% |
---|---|---|---|---|---|
1A2 | AUC0–t of caffeine in plasma | 16 | 0.869 | 0.786–0.961 | 16.2 |
Molar paraxanthine / caffeine plasma concentration ratio 6 h post-dose | 16 | 1.16 | 0.956–1.414 | 32.2 | |
2C9 | AUC0–t of tolbutamide in plasma | 16 | 1.035 | 0.973–1.101 | 10.0 |
Tolbutamide plasma concentration 24 h post-dose | 16 | 1.106 | 0.970–1.261 | 21.3 | |
2C19 | AUC0–t of omeprazole in plasma | 16 | 1.143 | 0.810–1.614 | 59.9 |
Molar omeprazole / 5-OH-omepazole plasma concentration ratio 3 h post-dose | 15b | 1.044 | 0.842–1.294 | 34.3 | |
Molar omeprazole / 5-OH-omepazole AUC0–t ratio | 16 | 1.111 | 0.998–1.237 | 17.4 | |
2D6 | AUC0–t of dextromethorphan in plasma | 15c | 1.046 | 0.838–1.305 | 36.7 |
Molar dextromethorphan / dextrorphan plasma concentration ratio 3 h post-dose | 15c | 1.131 | 0.962–1.328 | 25.2 | |
3A4 | AUC0–t of midazolam in plasma | 16 | 1.018 | 0.894–1.159 | 21.1 |
Midazolam plasma concentration 6 h post-dose | 16 | 1.040 | 0.847–1.277 | 33.8 |
AUC0–t, area under the plasma concentration-time curve between 0 and time of last quantifiable concentration; CI, confidence interval; CVintra, intrasubject coefficient of variation.
↵a The main phenotyping metrics are printed in bold.
↵b Concentration in one subject in the silexan period was below limit of quantification.
↵c One subject excluded because identified as genetically poor metabolizer.